<DOC>
	<DOCNO>NCT02826044</DOCNO>
	<brief_summary>SP2086 novel inhibitor Dipeptide base peptidase 4 , allow insulin-independent approach improve type 2 diabetes hyperglycemia . In single-dose multiple-dose study investigator evaluate safety , tolerability Pharmacokinetics profile SP2086 healthy volunteer .</brief_summary>
	<brief_title>The Pharmacokinetics Study Single Multiple Dose SP2086 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>BMI ( measure person 's weight relation height ) 19 26 kg/m2 , weight equal less 100kg . without history cardiovascular disease , liver disease , kidney disease , gastrointestinal tract disease , mental nerve disease drug allergy . Be willing accept physical contraception . Sign inform consent voluntarily ensure complete study . Known allergy SP2086 excipients formulation SP2086 ; ever occur myocardial infarction , acute coronary syndrome , transient ischemic attack . B hepatitis surface antigen hepatitis C antibody syphilis antibody HIV antibody positive . participate three clinical trial one year participate one time clinical medicine one month screening . history blood donation 3 month screen receive blood transfusion 1 month screen . history tobacco , alcohol drug abuse . History current clinically significant medical illness determine Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>